Shanghai perhum therapeutics

Author: kzbc

August undefined, 2024

Webb25 dec. 2024 · Shanghai PerHum Therapeutics Co., Ltd. 合作者 Shanghai Public Health Clinical Center 调查人员首席研究员：Tongyu Zhu、Shanghai Public Health Clinical Center 研究记录日期这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合 … Webb22 feb. 2024 · Contact Information Website www.perhum.com Formerly Known As Shanghai Weiming Xuhang Biotechnology Co., Ltd., Shanghai Xuhang Biotechnology Co., Ltd. Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Biotechnology Other Industries Laboratory Services (Healthcare) …

PerHum Therapeutics - Crunchbase Company Profile

WebbDeveloper EXUMA Biotech; Fudan University Zhongshan Hospital; Shanghai PerHum Therapeutics; Shanghai Sinobioway Sunterra Biotechnology Class CAR-T cell therapies; … Webb21 maj 2024 · EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor May 21, 2024, 9:00 … incautious self-overdosage

ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C …

Webb2 Shanghai PerHum Therapeutics Co. Ltd., Shanghai 200052, P.R. China. PMID: 32323752 DOI: 10.3892/ijmm.2024.4527 Abstract The expression of anillin mRNA and protein is regulated in a cell cycle‑dependent manner. However, the mechanism underlying ... WebbShanghai PerHum Therapeutics ("PerHum") was formed in 2016 for the express purpose of developing novel CAB-CAR-T therapies for solid tumor malignancies in China. Contact Who is Shanghai PerHum Therapeutics Headquarters Shanghai, Shanghai, China Phone Number +86 2134512787 Website www.perhum.com Revenue <$5M Industry Business … Webb21 maj 2024 · EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor CAR-T Products Data … in-and-for-itself

Targeting Axl-GAS6—a new option for tumor therapy – KACTUS

CCT301-59 和 CCT301-38 上肾细胞癌-临床试验注册中心-ICH GCP

Webb12 sep. 2024 · There are two main strategies to develop drugs targeting Axl-GAS6. One is to directly inhibit Axl, and the other is to inhibit GAS6 to prevent its binding to Axl, i.e., ligand capture. These drugs are suitable for tumor drug resistance therapy or … WebbA Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov) - P1 N=15 Recruiting Sponsor: Shanghai PerHum Therapeutics Co., Ltd. Trial completion date: Apr 2024 --> Oct 2024 Trial primary completion date: Apr 2024 --> Oct 2024. incaweb gallicumWebbMAINZ, Germany--(BUSINESS WIRE)--EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human solid tumor CAR-T … incaware

"Webb10 aug. 2024 · Shanghai PerHum Therapeutics Co., Ltd. Collaborator Shanghai Zhongshan Hospital Provider of Information About this Clinical Study Sponsor Conditions in This Trial Solid Tumor Gastric Cancer Breast Cancer Ovarian Cancer Sarcoma Additional Key Areas Provided by Investigators HER2 CAR-T Solid tumors Interventions in This Trial CCT303-406 " - Shanghai perhum therapeutics

Shanghai perhum therapeutics

CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or …

Webb13 nov. 2024 · SHANGHAI and WEST PALM BEACH, Fla., November 13, 2024 — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced that its international affiliate, EXUMA Biotechnology Hong Kong, has formed Shanghai EXUMA Biotechnology Co., Ltd., a … Webb22 mars 2024 · For HER2 Positive Breast Cancer Emerging drugs, the HER2 Positive Breast Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type ...

Did you know?

Webb10 apr. 2024 · Agile Therapeutics, Inc. PRINCETON, N.J., April 10, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that its board of ... Webb23 maj 2024 · - German biotechnology company Exuma biotechnology and affiliate Shanghai PerHum Therapeutics have presented interim results of two first-in-human …

Webb8 maj 2024 · 2024年10月19日更新者：Shanghai PerHum Therapeutics Co., Ltd. 基于安全性、耐受性和抗肿瘤活性研究评估 CAR（嵌合抗原受体）修饰的自体 T 细胞 CCT301-59 在复发性或难治性实体瘤患者中的应用。 Webb21 maj 2024 · MAINZ, Germany--(BUSINESS WIRE)-- EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human …

Webb10 nov. 2024 · May 5, 2024 updated by: Shanghai PerHum Therapeutics Co., Ltd. A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT301-38) in Patients With Relapsed or Refractory AXL Positive Sarcomas. http://asiatoday.com/pressrelease/exuma-biotechnology%E2%80%99s-affiliate-shanghai-perhum-therapeutics-announces-preliminary-resu

Webb21 maj 2024 · EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human solid tumor CAR-T products in subjects with recurrent or refractory stage IV metastatic renal cell carcinoma (mRCC).

Webb13 sep. 2024 · Shanghai Ming Ju Biotechnology Co., Ltd. ClinicalTrials.gov Identifier: NCT04089215 Other Study ID Numbers: JWCAR029-002 : First Posted: September 13, 2024 Key Record Dates: Last Update Posted: January 22, 2024 Last Verified: January 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No incax technologyWebb15 feb. 2024 · • The leading HER2-Positive Breast Cancer Companies includes Ambrx, Alteogen, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus... incawasiWebb21 maj 2024 · EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human solid tumor CAR-T products in … in-and-of itselfWebb10 nov. 2024 · Shanghai PerHum Therapeutics Co., Ltd. Collaborator. Shanghai Zhongshan Hospital; Provider of Information About this Clinical Study Sponsor; Overall Contact(s) Yuhong Zhou, M.D., +86-21-64041990, [email protected]; Conditions in This Trial. SAR; Additional Key Areas Provided by Investigators. incaxWebbPerhum therapeutics has developed a modified chimeric antigen receptor ... Shanghai Pu'er Biotechnology Overview. Founded Year 2016. Location Shanghai, China. Company Stage Funding Raised. Similar Cos. Ginkgo Bioworks, Human Longevity, Amyris, Bionano Genomics, Relay Therapeutics & 3271 others. incawich appliancesWebbShanghai PerHum Therapeutics Co., Ltd, a company incorporated in Shanghai in 2016, focuses on developing innovative cancer treatments in the field of adoptive cellular … in-and-out burger foundationWebb22 feb. 2024 · Contact Information Website www.perhum.com Formerly Known As Shanghai Weiming Xuhang Biotechnology Co., Ltd., Shanghai Xuhang Biotechnology Co., … in-and-of-itself